# Immune Responses to Tozinameran S Antigen ## What immune responses (neutralizing antibodies, cellular immunity) are induced by Tozinameran's spike (S) antigen expression? Tozinameran's spike antigen induces robust neutralizing antibody responses peaking at 2-4 weeks that decline over 6 months, alongside persistent spike-specific Th1-type CD4+ and cytotoxic CD8+ T cell responses with long-lived memory populations showing superior variant cross-reactivity. ## Abstract BNT162b2 (Tozinameran) vaccination induces robust spike-specific humoral and cellular immune responses in immunocompetent populations, with 95-98% seroconversion after two doses and peak neutralizing antibody levels at 2-4 weeks post-second dose. Antibody titers decline substantially over 6 months, with 50-90% reductions from peak levels, though this occurs alongside persistent spike-specific memory T and B cells capable of recall responses through 9 months. Cellular immunity emerges early, with T cell responses detectable by day 15, characterized by Th1-type CD4+ cells expressing IL-2, IFN-γ, and TNF-α and cytotoxic CD8+ responses. T stem cell memory populations persist stably through 6 months in 88% of individuals. Prior SARS-CoV-2 infection profoundly amplifies vaccine responses, with recovered individuals achieving peak neutralizing antibody titers after a single dose equivalent to two-dose vaccination in naïve individuals. However, immunocompromised populations show markedly attenuated responses, with dialysis patients achieving only 88.9% seroconversion and 67.7% T cell response rates compared to 93.3% in age-matched controls. Cellular immunity demonstrates superior cross-reactivity with variants compared to humoral responses. While Beta (B.1.351) variant neutralization shows 2- to 10-fold reductions, CD4+ T cell activation remains unaffected by mutations in B.1.1.7 and B.1.351 variants, with no significant differences in T cell responses against Beta and Delta variants. Age negatively correlates with antibody magnitude and persistence, while T cell responses decline in individuals with increased immunosenescent CD8+ TEMRA cells. Booster doses administered 6-12 months post-vaccination restore waning antibody responses, with greater benefit observed in naïve versus previously infected individuals. The evidence indicates Tozinameran’s spike antigen elicits complementary humoral and cellular immunity, with antibodies providing initial sterilizing protection that wanes over months while durable memory T cell populations persist to enable rapid recall responses upon antigen re-exposure. ## Methods We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question. ## Data Extraction ### Study Design - Study type (RCT, cohort, case series, etc.) - Sample size for immune response analysis - Population characteristics (age range, health status, occupation) - Prior SARS-CoV-2 infection status - Inclusion/exclusion criteria relevant to immune assessment - Study setting and duration of follow-up ### Tozinameran Administration - Number of doses administered - Dosing schedule and intervals between doses - Vaccine formulation/batch details if provided - Any deviations from standard protocol - Timing relative to prior SARS-CoV-2 infection if applicable ### Neutralizing Antibody Responses - Neutralizing antibody levels/titers at each timepoint - Seroconversion rates and timing - Neutralization capacity against original spike and variants - IgG and IgA antibody levels specific to spike protein - Comparison to controls or reference groups - Assay methods used (pseudovirus, live virus, etc.) - Geometric mean titers and fold-changes from baseline ### Cellular Immune Responses - CD4+ T cell responses (frequency, activation markers, cytokine production) - CD8+ T cell responses (frequency, cytotoxic markers, functionality) - Memory T cell formation and phenotypes - B cell responses and memory B cell development - T cell recall responses upon re-stimulation - Cross-reactivity with spike variants - Assay methods (ELISPOT, flow cytometry, IGRA, etc.) - Quantitative results and statistical comparisons ### Key Findings - Overall immunogenicity assessment - Relative strength of humoral vs. cellular responses - Clinical correlates of protection if discussed - Authors’ conclusions about spike antigen immunogenicity - Limitations or concerns about immune response quality ## Results ### Characteristics of Included Studies All 10 studies evaluated immune responses following BNT162b2 (Tozinameran) vaccination, with full texts available for 7 studies and abstract-only data for 3 studies. Study designs, populations, and follow-up durations varied substantially across the included evidence. ### Neutralizing Antibody Responses #### Seroconversion Rates and Antibody Titers Studies consistently demonstrated high seroconversion rates following two-dose vaccination in immunocompetent populations, though with notable variation in timing and magnitude. Among dialysis patients, only 55.6% developed SARS-CoV-2 IgG antibodies at the first sampling (~1 week post-second dose), increasing to 88.9% at 3-4 weeks and declining to 84.4% at 10 weeks. In contrast, 98.4% of immunocompetent naïve healthcare workers developed both neutralizing antibodies and specific T cells after the second dose. ### Neutralization Capacity Against Variants Studies evaluating variant cross-reactivity revealed differential neutralization capacity depending on the specific variant tested. For the B.1.1.7 (Alpha) variant, Geers et al. reported higher neutralizing antibody titers compared to wild-type virus. However, the B.1.351 (Beta) variant showed consistent immune escape, with decreases in neutralizing capacity and approximately 10-fold reduction in neutralizing antibody levels compared to the parent strain. ### Effects of Prior SARS-CoV-2 Infection Prior SARS-CoV-2 infection substantially amplified humoral responses. Recovered individuals achieved a geometric mean plateau PRNT50 titer significantly higher after a single vaccination than naïve individuals required to reach comparable levels after two doses. ### Cellular Immune Responses #### CD4+ and CD8+ T Cell Activation T cell responses were detected across multiple studies using various assay methods. Among dialysis patients, a significant percentage demonstrated SARS-CoV-2-specific T cell responses post-vaccination, though lower than age-matched controls. ### Memory T Cell Formation and Phenotypes Guerrera et al. provided detailed characterization of memory T cell phenotypes, demonstrating that BNT162b2 induced CD4+ T stem cell memory (TSCM), with levels increasing from baseline to 6 months. ### T Cell Cross-Reactivity with Variants In contrast to the partial escape observed with humoral immunity, cellular immunity demonstrated robust cross-reactivity across variants, with no significant differences in CD4+ T cell activation across the tested variants. ## Response Kinetics and Durability ### Temporal Dynamics of Immune Responses The kinetics of antibody and T cell responses followed distinct trajectories. Studies documented antibody responses appearing before peak levels, with significant declines noted at various intervals post-vaccination. ### Long-Term Persistence and Waning Immunity Long-term follow-up revealed a progressive decline in humoral immunity with more stable cellular responses, suggesting different patterns of memory cell persistence and contraction. ## Response Modifying Factors ### Age and Immunosenescence Age emerged as a consistent negative predictor of antibody responses across multiple studies, impacting both the magnitude and duration of these responses. ### Impact of Prior SARS-CoV-2 Infection Prior infection enhanced vaccine-induced immunity significantly across studies that examined this factor. ### Comorbidities and Immunocompromised States The study of dialysis patients highlights the profound impacts of chronic conditions on vaccine responses, demonstrating the need for modified strategies in these populations. ### Booster Dose Effects Booster doses significantly enhanced both humoral and cellular immune responses, indicating their importance in long-term vaccine efficacy. ## Synthesis The studies revealed substantial heterogeneity in immune response magnitude and durability, influenced by factors such as population characteristics, prior infection, age, and comorbid conditions. Overall, BNT162b2 induced robust immunity in immunocompetent individuals, while demonstrating varying degrees of effectiveness in immunocompromised populations. Cellular immunity proved more durable than humoral immunity, ensuring long-term protection against severe disease. ## References - Geers, D., Shamier, M., et al. (2021). SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Science immunology - Guerrera, G., Picozza, M., et al. (2021). BNT162b2 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory phenotype. Science immunology - Naaber, P., Tserel, L., et al. (2021). Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health - Europe - Payne, R., Longet, S., et al. (2021). Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell - Pulendran, B., Arunachalam, P. (2021). Systems biological assessment of human immunity to BNT162b2 mRNA vaccination. Research Square - Takeuchi, J., Fukunaga, A., et al. (2021). SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study. Scientific Reports - Desmecht, S., Tashkeev, A., et al. (2022). Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Frontiers in Immunology - El-Orfali, Y., Mansour, R. H., et al. (2025). Longitudinal T and B cell recall responses following vaccination with the Pfizer-BioNTech mRNA vaccine BNT162b2. Journal of Allergy and Clinical Immunology - Cassaniti, I., Bergami, F., et al. (2021). Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. Clinical Microbiology and Infection - Schrezenmeier, E., Bergfeld, L., et al. (2021). Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in Immunology.